What went well
- Financial Advisory achieved its strongest announced league-table position since 2014, with adjusted net revenue of $445 million in the quarter and $801 million for the first half.
- Asset Management delivered its best first-half net inflows in nearly 20 years (~$7.4-$7.5 billion) and reached record AUM of $285 billion (up 15% year-over-year), with management fees up 23% year-over-year to $310 million.
- Restructuring and Liability Management posted its best first-half performance in almost a decade, and Private Capital Advisory saw increased client demand ahead of the Lazard CL launch.
- Forward indicators strengthened materially: dollar-weighted conflict clearances rose ~40% year-over-year (over 100% for deals above $5 billion), and the weighted 2027 pipeline is already more than twice the level 2026 was at the same time last year.
- The firm restarted share buybacks (after pausing for the Campbell Lutyens deal) with a ~$250 million authorization, returned $103 million to shareholders in the quarter, and raised the quarterly dividend to $0.50 per share.
- The Lazard Advantage quantitative platform more than doubled to $50 billion in AUM over the past year, and the U.S. active ETF platform surpassed $2 billion by July, well under a year after launch.
What went wrong
- GAAP net income was just $5 million ($0.03 per diluted share), driven down by an anomalous 69.7% adjusted effective tax rate tied to a catch-up adjustment on the vesting of equity (not indicative of the high-20% full-year rate).
- The adjusted compensation ratio remained elevated at 69.9%, with the firm accruing at the same level as Q1, reflecting the MD-repositioning J-curve and elevated amortization from ~90 gross lateral hires since 2023.
- First-half revenue came in lighter than the firm had expected at the end of last year, as the advisory business worked through its transitional MD turnover.
- Asset Management had net outflows of $1.6 billion in the second quarter (though first-half net flows remained strongly positive), reflecting the inherent lumpiness of institutional mandates.
- Private equity M&A remained subdued on a valuation gap and higher-for-longer rates, and management flagged a possible slight dip in MD productivity this year given the large number of newly added managing directors.
Guidance Changes
| Metric | Period | Current guidance |
|---|---|---|
| Second-half revenue seasonality | 2H 2026 | Firm-wide revenue stronger in 2H than 1H (Financial Advisory-driven), a more pronounced pattern than usual this year |
| Effective tax rate | FY2026 | High-20% range on a GAAP basis (Q2's 69.7% was anomalous) |
| Compensation ratio | 2H 2026 / 2027-2028 | Can come down in 2H if FA revenue performs; a significant, material decline expected across 2027 and 2028 |
| Non-compensation expense growth | FY2026 | Mid-to-high single digits (possibly up a point or two; some Campbell Lutyens-related noise) |
| Lazard CL (Campbell Lutyens) revenue | 2027 | ~$500 million (accretive to earnings in 2027 and thereafter, before synergies) |
| Asset Management net flows | FY2026 | On track for positive net flows for the year |
| MD productivity target | 2028 | $10 million per MD (on track) |
| Advisory MD count | Q1 2027 | At least 248 (10-15 net adds per year) |
Performance Breakdown
| Metric | YoY | Note |
|---|---|---|
| Firm-wide adjusted net revenue | $786M (Q2), $1.5B (H1) | Financial Advisory M&A completions in North America plus record Asset Management fees, as the firm emerges from the MD J-curve. |
| GAAP net revenue | +1.5% to $808M | Total revenue $830.2M less interest expense; modest year-over-year growth as advisory recovers. |
| GAAP diluted EPS | $0.03 (GAAP net income $5M) | Depressed by a one-time 69.7% adjusted effective tax rate from an equity-vesting catch-up adjustment. |
| Financial Advisory adjusted net revenue | $445M (Q2), $801M (H1) | North American M&A completions, strong London advisory, and a near-decade-best Restructuring & Liability Management half. |
| Asset Management adjusted net revenue | $331M (Q2), $640M (H1) | Management fees up 23% YoY to $310M on higher average AUM ($279B, +17% YoY) and $27B of market appreciation. |
| AUM | +15% to $285B (record) | $7.4B H1 net inflows, market appreciation, and an Allied Partners consolidation; best first-half inflows in nearly 20 years. |
| Adjusted compensation ratio | 69.9% | Held at the Q1 accrual level pending clarity on Campbell Lutyens close, hiring moderation, and pipeline build; weighed by the MD repositioning. |
| Adjusted non-compensation ratio | 21.8% ($172M) | Investment in the platform and technology; AI/token spend still immaterial. |
Earnings Call Themes & Trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Lazard 2030 plan (relevance, revenue, returns) | Launched ~3 years ago | Tangible progress across all three: best FA league-table position since 2014, best AM first-half inflows in ~20 years and record AUM, reinforcing confidence in long-term profitable growth. | — |
| Advisory MD J-curve / repositioning | Turned over ~40% of advisory MDs | ~90 gross hires since 2023 created a revenue/comp headwind now flipping to a tailwind; newly hired MDs' average productivity after two years already exceeds that of separated MDs, with 238 MDs today heading to 248+ by Q1 2027 and $10M/MD targeted by 2028. | — |
| Campbell Lutyens / Lazard CL | Announced acquisition | Integration well underway to create a third business (global private capital advisory), expected to generate ~$500M of revenue in 2027 and be accretive in 2027+ before synergies, with strong secondaries/continuation-fund demand. | — |
| Strategic vs. sponsor M&A divergence | Robust but concentrated activity | M&A is skewed to large strategic deals (conflict clearances +100% for >$5B) while private equity M&A stays subdued on a valuation gap; rising LP distribution pressure and alternative-manager commentary suggest a coming shift that would make forward indicators even stronger. | — |
| Asset Management transformation | Platform and leadership overhaul | New CIO, COO, and incoming heads of product and corporate development; 68% of AUM outperforming benchmarks over five years, broad-based inflows (systematic/Advantage, EM, Japan, infrastructure, fixed income), and a won-but-not-funded pipeline above year-end 2025. | — |
| AI adoption | Multi-model, inside-the-firewall strategy | Rolled out Claude alongside multiple models (avoiding single-vendor lock-in), embedding AI across research, portfolio construction, and client servicing; spend/token cost remains immaterial, with the key signal being cultural adoption and a strong ROI. | — |
| Compensation-ratio trajectory | Elevated on repositioning | Management expects a significant multi-year decline into 2027-2028 from three effects: the fade of one-time buyout/amortization costs, operating leverage on rising per-MD productivity, and direct efficiency initiatives (smaller deal teams, corporate-function review). | — |
| Capital allocation | Buybacks paused for Campbell Lutyens | Buybacks restarted (~$250M authorization) and expected to continue, dividend raised to $0.50, with the restart signaling no near-term inorganic process precluding repurchases even as the firm actively evaluates options. | — |
Q&A Summary
Gab Angelini (Bank of America) asked why strategic and sponsor M&A have diverged year-to-date and the outlook for sponsor activity, plus the key Asset Management changes and KPIs.
Peter Orszag attributed the divergence to a valuation gap from higher rates that discourages sponsors from selling, offset by building LP distribution pressure (an accelerant for secondaries/continuation funds where Lazard/Campbell Lutyens is well-positioned); Chris Hogbin cited a new CIO and COO, AI adoption, 68% of AUM beating five-year benchmarks, and $7.5B of H1 net inflows as trackable progress.
Brennan Hawken (BMO) asked for color on the more pronounced second-half advisory seasonality and on the quarter-over-quarter decline in MD headcount.
Tracy Farr said the lighter first half and the pace of pipeline build make the usual 2H-over-1H strength more pronounced this year; Orszag said to ignore quarterly MD fluctuations (garden-leave/separation timing), with tenured MDs set to more than triple from 2023 to 2028 and ramping disproportionately in healthcare, industrials, technology, and private capital.
Mike Brown (UBS) asked about second-half Asset Management flow puts and takes and whether the strong first half can continue, plus whether FA can drive the comp ratio to ~65.5%.
Hogbin cited broad product and geographic breadth (Advantage doubled to $50B, EM, infrastructure, Japan, fixed income) and a won-but-not-funded pipeline above year-end, with retail steady and institutional lumpier; Farr said the comp ratio is indexed to second-half FA performance and could improve, without committing to a level.
James Yaro (Goldman Sachs) asked how AI can benefit Lazard's strategic advisory and secondaries, and whether anything (pull-forwards) changed the strong quarter.
Orszag pointed to matching strategics with private/insurance capital, a rich GP/LP data asset from the Lazard CL combination, and AI deployment to banking/AM teams; he said there were no exceptional pull-forwards, just increasing momentum as the firm emerges from the J-curve.
Connell Schmitz (Morgan Stanley) asked about the Claude rollout and AI strategy, non-comp expense trajectory, and corporate-overhead reduction progress.
Orszag framed Claude as consistent with a deliberate multi-model, no-single-source strategy focused on cultural change, with spend still immaterial; Farr described efficiency work (smaller deal teams, AM headcount reductions, a back-office review) aimed at sticky structural change that decouples corporate-cost growth from revenue.
Steven Chubak (Wolfe Research) asked about the comp trajectory beyond 2026 and momentum in the non-M&A businesses.
Orszag and Farr described three forces driving a significant comp-ratio decline in 2027-2028 (fading one-time buyout/amortization costs, operating leverage on rising per-MD productivity, and direct efficiencies), with the revenue tailwind arriving in 2027 and comp normalizing by 2028; non-M&A (PCA, restructuring/liability management) is trending healthily and will expand with Lazard CL.
Devin Ryan (Citizens JMP) asked what is driving the acceleration in $5 billion-plus conflict clearances.
Orszag clarified the >100% figure is fee-weighted and attributed the large-cap uplift to three things: a market skewed toward large strategic deals, a deliberate leadership initiative to raise league-table and large-cap prominence, and Lazard's talent plus 'contextual alpha' (incorporating geopolitics) winning more boardroom access.
Alex Bond (KBW) asked whether the sub-$5 billion deal cohort is picking up and whether the mid-to-high-single-digit non-comp growth guide still holds.
Orszag said a sub-$5B pickup largely depends on private equity reawakening (forward indicators are strong despite subdued sponsor activity); Farr confirmed non-comp growth guidance holds (maybe up a point or two, with some Campbell Lutyens noise), AI spend rising but immaterial, and higher client-convening travel viewed as a revenue driver offset by other savings.
More on Lazard, Inc.
Reported 2026-07-23 · figures from the Lazard, Inc. Q2 2026 earnings call.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.